Impact of frailty, melphalan pharmacokinetics, and pharmacogenetics on outcomes post autologous hematopoietic cell transplantation for multiple myeloma-Reference-Cited by-同舟云学术

Impact of frailty, melphalan pharmacokinetics, and pharmacogenetics on outcomes post autologous hematopoietic cell transplantation for multiple myeloma

Published:2019-08-12 Issue:12 Volume:54 Page:2088-2095
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Nampoothiri Ram V.,Kasudhan Kripa Shanker,Patil Amol N.,Malhotra Pankaj^ORCID,Khadwal Alka,Prakash Gaurav,Jain Arihant,Malhotra Samir,Verma Attri Savita,Varma Neelam,Varma Subhash,Lad Deepesh P.^ORCID

Funder

DST | Science and Engineering Research Board

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

http://www.nature.com/articles/s41409-019-0631-0.pdf

Reference39 articles.

1. Jain T, Sonbol MB, Firwana B, Kolla KR, Almader-Douglas D, Palmer J, et al. High-dose chemotherapy with early autologous stem cell transplantation compared to standard dose chemotherapy or delayed transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis. Biol Blood Marrow Transplant .2019;25:239–47.

2. Dhakal B, Szabo A, Chhabra S, Hamadani M, D’Souza A, Usmani SZ, et al. Autologous transplantation for newly diagnosed multiple myeloma in the era of novel agent induction: a systematic review and meta-analysis. JAMA Oncol. 2018;4:343–50.

3. Jagannath S, Vesole DH, Glenn L, Crowley J, Barlogie B. Low-risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support. Blood. 1992;80:1666–72.